Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry

References

Page 1

	Year	Citations
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg, Journal of Hepatology Hepatitis DViral HepatitisHepatitis BHepatitisAntiviral Therapy	2017	5.3K
Natural history of liver fibrosis progression in patients with chronic hepatitis C Thierry Poynard, Pierre Bédossa, P Opolon The Lancet Liver Fibrosis ProgressionHepatologyHepatitis CViral HepatitisLiver Physiology	1997	3K
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection Journal of Hepatology	2013	856
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 Stefan Zeuzem, Geoffrey Dusheiko, Riina Salupere, New England Journal of Medicine	2014	796
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C Thierry Poynard, Vlad Ratziu, Frédéric Charlotte, Journal of Hepatology Liver Fibrosis ProgressionHepatologyHepatitis CViral HepatitisLiver Physiology	2001	747
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) Vincent Leroy, Peter Angus, Jean–Pierre Bronowicki, Hepatology	2016	278
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis K. Rajender Reddy, Marc Bourlière, Mark Sulkowski, Hepatology	2015	255
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort Tania M. Welzel, Jörg Petersen, Kerstin Herzer, Gut	2016	196
Progression to cirrhosis in hepatitis C patients: an age‐dependent process Pierre Pradat, Nicolas Voirin, Hans L. Tillmann, Liver International	2007	97
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection Manfred Wiese, Janett Fischer, Micha Löbermann, Hepatology	2013	92

Page 1